Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FGFR1 | P11362 | 4/20 | 0.58 |
| ▸ | FGFR4 | P22455 | 3/20 | 0.58 |
| ▸ | FGFR2 | P21802 | 2/20 | 0.58 |
| ▸ | FGFR3 | P22607 | 2/20 | 0.58 |
| ▸ | SRC | P12931 | 2/20 | 0.58 |
| ▸ | WEE1 | P30291 | 2/20 | 0.56 |
| ▸ | PAK1 | Q13153 | 3/20 | 0.55 |
| ▸ | PKN1 | Q16512 | 3/20 | 0.55 |
| ▸ | PAK4 | O96013 | 2/20 | 0.55 |
| ▸ | TNK2 | Q07912 | 6/20 | 0.54 |
| ▸ | CDK4 | P11802 | 5/20 | 0.54 |
| ▸ | AURKA | O14965 | 1/20 | 0.54 |
| ▸ | CCND1 | P24385 | 4/20 | 0.53 |
| ▸ | CCND2 | P30279 | 3/20 | 0.53 |
| ▸ | CCND3 | P30281 | 3/20 | 0.53 |
| ▸ | CCNA2 | P20248 | 3/20 | 0.52 |
| ▸ | CCNE1 | P24864 | 3/20 | 0.52 |
| ▸ | CDK2 | P24941 | 3/20 | 0.52 |
| ▸ | CDK1 | P06493 | 2/20 | 0.52 |
| ▸ | CCNB1 | P14635 | 2/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16510428 | 0.94 | PAK1 (0.65) | FGFR1FGFR4FGFR2FGFR3SRC | |
| SCHEMBL15035279 | 0.93 | PAK1 (0.56) | FGFR1FGFR4FGFR2FGFR3SRC | |
| SCHEMBL15035274 | 0.86 | FGFR1 (0.58) | FGFR1FGFR4FGFR2FGFR3SRC | |
| SCHEMBL15035277 | 0.86 | FGFR1 (0.58) | FGFR1FGFR4FGFR2FGFR3SRC | |
| SCHEMBL15035282 | 0.86 | FGFR1 (0.58) | FGFR1FGFR4FGFR2FGFR3SRC | |
| SCHEMBL15041300 | 0.85 | CDK4 (0.73) | FGFR1FGFR4FGFR2FGFR3PAK1 | |
| SCHEMBL15035267 | 0.85 | PAK3 (0.58) | FGFR1FGFR4FGFR2FGFR3SRC | |
| SCHEMBL15035250 | 0.84 | TNK2 (0.43) | FGFR1FGFR4FGFR2FGFR3SRC | |
| SCHEMBL16510433 | 0.80 | PAK1 (0.64) | FGFR1FGFR4FGFR2FGFR3SRC | |
| SCHEMBL16510431 | 0.80 | PAK1 (0.64) | FGFR1FGFR4FGFR2FGFR3SRC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130158043-A1 | PAK INHIBITORS FOR THE TREATMENT OF CANCER | AFRAXIS, INC. (US) | 2013-06-20 | — | — | US | disclosed |
| US-20130158043-A1 | PAK INHIBITORS FOR THE TREATMENT OF CANCER | AFRAXIS, INC. (US) | 2013-06-20 | — | — | US | disclosed |
| WO-2011156775-A2 | 8-(2'-HETEROCYCYL)PYRIDO[2.3-D]PYRIMIDIN-7(8H)-ONES FOR THE TREATMENT OF CNS DISORDERS | AFRAXIS, INC. (US) | 2011-12-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130158043-A1 | PAK INHIBITORS FOR THE TREATMENT OF CANCER | PAK5, PAK2, PAK6 | FGFR1 1919/4885FGFR4 1949/4885FGFR2 1706/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.